Ocugen (OCGN) vs. Its Rivals Head-To-Head Analysis

Ocugen (NASDAQ:OCGN) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Ocugen to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Valuation and Earnings

This table compares Ocugen and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ocugen	$4.41 million	-$67.85 million	-4.62
Ocugen Competitors	$691.14 million	$10.43 million	-15.00

Ocugen’s rivals have higher revenue and earnings than Ocugen. Ocugen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

10.3% of Ocugen shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Ocugen and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Ocugen Competitors	-9,046.59%	-199.78%	-30.61%

Volatility & Risk

Ocugen has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Ocugen’s rivals have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ocugen and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1	0	4	0	2.60
Ocugen Competitors	9828	15119	45430	1586	2.54

Ocugen presently has a consensus target price of $9.50, indicating a potential upside of 927.03%. As a group, “Biotechnology” companies have a potential upside of 102.57%. Given Ocugen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than its rivals.

Summary

Ocugen rivals beat Ocugen on 7 of the 13 factors compared.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.